theMednetRegister

Pulmonology

Rheumatology   

Questions discussed in this category

How do you approach PJP prophylaxis in patients with rheumatic disease on corticosteroids?
Does the presence of ILD change your approach?
3 Answers available
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
1 Answer available
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
2 Answers available
What is your approach to treatment of airway involvement, such as recurrent bronchial stenosis, in relapsing polychondritis?
Are there specific immunosuppressive agents effective for this manifestation?
1 Answer available
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
Pre-treatment troponin was mildly elevated, while ILR2 receptor, ACE, CRP, ESR were normal. 
1 Answer available
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
For example, is captopril dialyzable? 
1 Answer available
What is your preferred first-line treatment for chronic fatigue in patients with long COVID-19?
7 Answers available
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
2 Answers available
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
1 Answer available
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
4 Answers available
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Do you use TNF-i or MMF?
1 Answer available
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Is this managed as CTD-ILD with immunosuppressive +/- anti-fibrotic agents?
1 Answer available
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
1 Answer available
How do you approach a patient on anti-TNF with positive Quantiferon (previously negative) with negative chest x-ray and no symptoms?
7 Answers available
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
1 Answer available
How would you manage a patient with ANCA associated vasculitis who has recurrent flare including pulmonary hemorrhage, persistent MPO antibody positivity while on maintenance rituximab and avacopan regimen even after induction rituximab therapy?
1 Answer available
Do you start immunosuppression for enlarging pulmonary nodules without symptoms, impaired pulmonary function, or extra-pulmonary disease in a patient with sarcoidosis?
1 Answer available
How do you workup patients with neuropathy suspected to be secondary to sarcoid?
Is a biopsy or EMG helpful in confirming the etiology? What is the best treatment for sarcoid neuropathy?
1 Answer available
What would be your recommendation for treatment of worsening lung disease in a patient with long-standing scleroderma after long-term mycophenolate therapy which is no longer an option due to side effect/intolerance?
3 Answers available
Is there a role for the use of transient elastography (FibroScan) to monitor liver fibrosis in patients on long term methotrexate?
3 Answers available
How would you approach the workup and management of isolated inflammatory subglottic stenosis in a young previously healthy patient that is steroid responsive with a completely negative serologic autoimmune workup?
Would you push for biopsy before deciding on treatment?
1 Answer available
How do you approach management of new onset ILD in a patient with RA who is otherwise well controlled on methotrexate or leflunomide?
1 Answer available
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
2 Answers available
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
CT changes are subsolid and ground glass nodules.
1 Answer available
How do you approach medication management in biopsy-proven pulmonary sarcoidosis with disease stable for over 2 years on hydroxychloroquine and low dose prednisone?
Do you discontinue HCQ?
2 Answers available
How do you approach the treatment of indeterminate UIP on HRCT with grossly positive MPO antibody and no other features consistent with AAV?
1 Answer available
What is your approach to tapering therapy in patients with pulmonary sarcoidosis who are asymptomatic with stable pulmonary function and imaging?
1 Answer available
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA
1 Answer available
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
1 Answer available
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
Do you ever start mycophenolate without steroids?
1 Answer available
How would you approach a pulmonary-renal PR3+ ANCA vasculitis patient who has persistent re-narrowing of mainstem bronchus after several dilatation and stenting procedures, with other anca features well-controlled on rituximab & avacopan?
5 Answers available
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Would it be safe to resume and if so, when?
2 Answers available
Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?
2 Answers available
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?
6 Answers available
What serologic biomarkers do you send to assess for sarcoidosis at baseline and/or during flares, in patients where it may correlate with disease activity?
Specifically, do you check for any of these: ACE, Vitamin D 1,25, serum lysozyme, soluble IL2 or Adenosine deaminase levels?
1 Answer available
How do you approach management of adult patients with CVID and sarcoid-like syndrome?
1 Answer available
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
1 Answer available
Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?
2 Answers available
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
2 Answers available
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
How do you manage diarrhea in a patient with CTD-ILD on MMF who was recently started on full dose nintedanib?
5 Answers available
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
1 Answer available
What protective post-op measures do you recommend for a patient with scleroderma and a history of ILD, PH, Raynaud’s and digital ischemia undergoing cardiothoracic surgery?
1 Answer available
How do you approach biologic initiation in patients with inflammatory arthritis and repeatedly indeterminate Quantiferon?
5 Answers available
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
1 Answer available
How do you approach treating and monitoring sarcoidosis manifested by maxillary bone/teeth loss without other symptoms?
3 Answers available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
2 Answers available
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
Given poor pulmonary outcomes in people with anti-PL12 antibodies, would you recommend more aggressive therapy? The patient was diagnosed with onset o...
1 Answer available
How would you manage asymptomatic osseous sarcoidosis of the lumbar spine without any other systemic involvement?
Would you use with DMARDs/biologics or monitor?
1 Answer available
What is your approach for disease activity monitoring in patients with sarcoidosis?
1 Answer available
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
1 Answer available
Do you consider pulmonary hypertension related to sarcoidosis to be an indication to start steroids?
Do you use biomarkers or PET scanning to stratify patients who may benefit most from therapy?
1 Answer available
How would you approach medication de-escalation in a patient with a history of rapidly progressive CTD-ILD who responded to and is currently on mycophenolate 3 grams daily and IVIG 2mg/kg monthly infusions and has been stable for two years?
2 Answers available
How do you approach management of a patient with Sjogren's disease and lung mass biopsy revealing amyloidosis?
1 Answer available
How do you approach management of a patient with idiopathic PAH and +ANA, but no other current symptoms/signs of active rheumatologic disease?
3 Answers available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).
2 Answers available
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
3 Answers available
What is your approach to monitoring patients with cardiac sarcoid while tapering immunosuppression?
Do you obtain serial cardiac PET scans?
1 Answer available
What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?
2 Answers available
What are best practices in management of severe acute infusion reaction from infliximab?
Patient became acutely flushed, developed severe and prolonged hypotension with brief loss of consciousness, dizziness, nausea, dry heaves and headach...
1 Answer available
What is your approach to a patient who has a cardiac PET scan suggestive of sarcoid but no other supporting evidence of a diagnosis of sarcoid?
Do you typically push for myocardial biopsy in this case? 
1 Answer available
What is your approach in differentiating IPAF (interstitial pneumonia with autoimmune features) versus "CTD ILD" in patients with serologic abnormalities but do not fulfill criteria for autoimmune disease?
1 Answer available
Have you seen rheumatoid nodules or RA-ILD in patients with seronegative RA?
While classically described as seen in seropositive patients, have they been reported in seronegative RA?
2 Answers available
What is the risk of ILD recurrence in MDA5/Ro52 positive dermatomyositis following a lung transplantation?
2 Answers available
What is your initial treatment of choice in patients with RA and associated interstitial lung disease?
1 Answer available
What is your approach to using nintedanib in patients on baseline immunosuppression?
Patients on baseline mycophenolate and azathioprine were excluded from the INBUILD trial however many patients with CTD-ILD will be on some form of im...
5 Answers available
What is your preferred steroid sparing agent in the treatment of Sjögren associated LIP?
2 Answers available
What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?
2 Answers available
How do you approach treating mild hypercalcemia in patients with sarcoidosis?
1 Answer available
When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?
Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?
6 Answers available
What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?
When adding nintedanib what sort of treatment course do you counsel the patient on? Do you plan to continue it indefinitely as long as the patient tol...
3 Answers available
Do you generally recommend starting nintedanib prior to immunosuppressive therapy in a patient with CTD-ILD?
Do you prefer to start with nintedanib and then add immunosuppressive agents, or give a trial of immunosuppressive medication first, then add nintedan...
4 Answers available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
What dose and duration of steroid therapy do you use in steroid responsive ILD?
1 Answer available
Do you continue methotrexate while starting TNFi therapy in patients with refractory pulmonary sarcoidosis?
3 Answers available
How do you manage recurrent inflammatory pleural effusions in lupus pleuritis?
1 Answer available
What is your approach to therapy for pulmonary sarcoidosis resistant to methotrexate?
1 Answer available
How would you manage immune check point inhibitor induced capillary leak syndrome refractory to IVIG monotherapy?
1 Answer available
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
Are there known biomarkers predictive of IRAEs?
3 Answers available
Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?
1 Answer available
How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?
4 Answers available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available
How would you manage subclinical ILD associated with MDA-5 Dermatomyositis?
Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?
1 Answer available
Would you consider PLEX for patients with DAH from SLE-associated capillaritis?
1 Answer available
What workup do you do for patients who have PL-7 elevation when screening for myopathy?
2 Answers available
Is there a role for immunosuppression in addition to standard PAH therapy in the management of pulmonary hypertension associated with primary Sjogrens syndrome?
Assuming other non CTD related causes for PAH have been excluded
1 Answer available
How do you clinically distinguish between group I and group III PH in patients with CTD-ILD?
1 Answer available
Do you utilize soluble IL-2 receptor or ACE levels as serum biomarkers to monitor disease activity in pulmonary sarcoidosis?
1 Answer available
How do you treat patients with sarcoid who have persistent symptoms after an initial 6 week course of corticosteroids?
3 Answers available
Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD who have not yet demonstrated evidence of a progressive phenotype?
1 Answer available
What is your approach to treatment for a patient with progressive ILD (UIP pattern) with high titer RF but no articular symptoms?
1 Answer available
Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?
Would you suggest switching to a viral vector vaccine, such as J&J?
2 Answers available
How do you treat multisystem sarcoidosis refractory to methotrexate, humira, and remicade?
2 Answers available
How would you approach treatment for fulminant RA-associated ILD?
Would you discontinue Methotrexate and TNF inhibitors even if previously no side effects from these medications, and would you consider Cyclophosphami...
1 Answer available
What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2 Answers available
What criteria do you use on echocardiogram and PFT to determine who needs further evaluation for CTD-associated pulmonary hypertension?
1 Answer available
What indicators do you use to identify patients with CTD-ILD who do not have potential to improve from continued immunosuppressive therapy?
Do you use imaging (fibrosis vs. pneumonitis), PFTs, duration of prior immunosuppressive therapy?
1 Answer available
What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?
1 Answer available
How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?
Would you change rituximab maintenance dose or schedule?
1 Answer available
How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?
1 Answer available
What immunosuppressive agents aside from steroids would you use to treat bronchiolitis obliterans in a patient with long-standing seropositive RA?
1 Answer available
How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?
1 Answer available
How do you treat an AAV patient with recurrent bronchial stenosis that has not responded to rituximab induction therapy and dilatations?
1 Answer available
Are there any concerns about using nintedanib in a patient with progressive fibrosing ILD on background mycophenolate?
1 Answer available
How do you treat CTD-associated organizing pneumonia?
How is your approach to treatment different than other ILD patterns such as NSIP? Does treatment response vary based on underlying CTD?
2 Answers available
How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?
1 Answer available
How do you treat RA in patients with pulmonary mycobacterium avium complex (MAC) infections?
1 Answer available
What is your approach to treatment for MDA5 dermatomyositis patients with rapidly progressive ILD?
Cyclophosphamide/tacrolimus and Rituximab have been used in conjunction with steroids in case series.
1 Answer available
Is there a role for anti-IL6 therapy in SSc-associated ILD?
1 Answer available
Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?
1 Answer available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?
1 Answer available
What steroid sparing agent do you use for treatment of cardiac sarcoidosis?
Does the type of cardiac involvement impact this choice?
2 Answers available
Should MTX be avoided in RA patients with asymptomatic lung nodules?
If so, what would be an ideal DMARD in this setting?
1 Answer available
Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?
2 Answers available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?
1 Answer available
How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?
1 Answer available
What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?
1 Answer available
Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
 If you use both, how do you decide which to use for a particular patient?
2 Answers available
What is the role of nintedanib in the treatment of SSc-ILD?
The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...
2 Answers available
When do you use tacrolimus in patients with myositis-related interstitial lung disease?
1 Answer available
What agent do you try next in patients with myositis-related interstitial lung disease who are refractory to mycophenolate mofetil and azathioprine?
1 Answer available
When do you stop immunosuppressants in patients with GPA?
1 Answer available
What is your next step in patients with polymyositis without interstitial lung disease who are refractory to methotrexate?
1 Answer available
How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?
Is IO related pneumonitis in the radiation field or more diffuse?
1 Answer available


Papers discussed in this category

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004
Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
The New England journal of medicine, 2015-07-16
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Medicine (Baltimore),
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
The New England journal of medicine, 2006-06-22
Cyclophosphamide versus placebo in scleroderma lung disease.
Archives of internal medicine, 2008-09-22
Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.
Arthritis and rheumatism, 2010-06
Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Ann. Rheum. Dis., 2017 May 25
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Semin Arthritis Rheum, 2020 Jun
TNF-alpha inhibition for the treatment of cardiac sarcoidosis.
Intern Med, 2014 Dec 01
Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.
J Am Heart Assoc, 2019 Sep 06
Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.
Clin Rheumatol, 2007 Mar 30
Cardiac sarcoidosis responding to monotherapy with infliximab.
The New England journal of medicine, 2017-05-18
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Kidney international reports, 2018-03
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
Rheumatology (Oxford),
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Lancet Respir Med, 2020 Aug 28
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
N Engl J Med,
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Nature reviews. Rheumatology, 2018-05
Treatment in myositis.
Trials, 2017 Jun 15
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Arthritis Rheumatol, 2021 Feb 03
Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease.
N Engl J Med, 2012 May 20
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
J Heart Lung Transplant, 2021 Nov
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Interact Cardiovasc Thorac Surg, 2015 Jan 07
Recurrent polymyositis-associated lung disease after lung transplantation.
Rheumatology (Oxford, England), 2011 Dec 30
Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission.
Annals of the rheumatic diseases, 2022 Nov 03
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.
Frontiers in immunology, 2021 Apr 12
Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumonia in Immunocompromised Patients.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
J Immunother Cancer, 2021 Feb
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
J Natl Compr Canc Netw,
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Ann Oncol,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J Immunother Cancer,
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
J Immunother Cancer,
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
J Clin Oncol, 2021 Dec 20
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
J Natl Compr Canc Netw,
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Ann Intern Med,
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Rheum Dis, 2011 Nov 29
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Respir Med, 2012 Apr 09
The treatment of pulmonary sarcoidosis.
Am J Respir Crit Care Med,
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
Arthritis Rheum,
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Eur Heart J, 2015 Aug 29
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Eur Respir J, 2019 Jan 24
Diagnosis of pulmonary hypertension.
BMJ Open, 2019 May 05
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
The European respiratory journal, 2014-11
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
Clin Exp Rheumatol, 2019 Nov 20
Use of third-line therapies in advanced sarcoidosis.
N Engl J Med,
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Lung, 2021 Apr 07
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
RMD Open, 2021 Sep
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Drugs,
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.
Eur Respir J, 2021 Dec 16
ERS clinical practice guidelines on treatment of sarcoidosis.
The European respiratory journal, 2015-10
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Scientific reports, 2017 Aug 10
Analysis of Factors Influencing Diagnostic Accuracy of T-SPOT.TB for Active Tuberculosis in Clinical Practice.
The European respiratory journal, 2019-01
Risk stratification and medical therapy of pulmonary arterial hypertension.
Eur Respir J, 2019 Jan 24
Pulmonary hypertension in chronic lung disease and hypoxia.
Chest, 2021 Feb
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
Medical sciences (Basel, Switzerland), 2018-09-21
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
The Journal of clinical investigation, 2021 Dec 15
The intersection of COVID-19 and autoimmunity.
Molecular systems biology, 2023 Mar 15
A methylation clock model of mild SARS-CoV-2 infection provides insight into immune dysregulation.
BMJ open, 2024 May 13
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
Rheumatology (Oxford, England), 2017-06-01
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Autoimmun Rev, 2012 Jul 05
Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Lancet Respir Med, 2021 Jan
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Lupus, 2020 Feb 09
Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies.
Future Sci OA, 2020 Aug 03
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.
Cancer Treat Res Commun, 2022 Jul 01
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Trends Immunol, 2021 Mar 10
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2022 Jun 11
Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features.
European respiratory review : an official journal of the European Respiratory Society, 2021 Dec 22
Interstitial pneumonia with autoimmune features: challenges and controversies.
Respirology, 2013 Nov 29
Rituximab in severe, treatment-refractory interstitial lung disease.
Respir Res, 2022 Jun 21
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
AACE Clin Case Rep, 2020 Aug 06
METHOTREXATE TREATMENT FOR SARCOIDOSIS-INDUCED HYPERCALCEMIA.
Am J Med, 1987 Jun
Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis.
Sarcoidosis Vasc Diffuse Lung Dis, 2012 Mar
Hypercalcemia from sarcoidosis successfully treated with infliximab.
Arch Osteoporos, 2017 Jul 19
Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia.
BMJ Case Rep, 2022 Jul 08
Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.
Arthritis Res Ther, 2014 Mar 24
Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients.
European journal of internal medicine, 2023 Sep 04
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Clin Med Insights Circ Respir Pulm Med, 2021 Mar 30
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.
Cureus, 2022 Sep 06
Mycophenolate Mofetil-Induced Cytomegalovirus Colitis in a Patient With Polymyositis.
Respir Res, 2023 Jan 9
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Respiratory medicine, 2016-12
Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
Arthritis Care Res (Hoboken), 2016 Jan
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Alimentary pharmacology & therapeutics, 2022 May 20
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
Arthritis & rheumatology (Hoboken, N.J.), 2015-05
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
International journal of rheumatic diseases, 2014-02
Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Clinical nuclear medicine, 2016-05
FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.
J Investig Med High Impact Case Rep, 2021 Jan-Dec
Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.
Clinical therapeutics, 2018 Feb
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
The American journal of gastroenterology, 2003 Jun
The incidence and management of infusion reactions to infliximab: a large center experience.
The Journal of rheumatology, 2015 Jun 15
Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
Heart rhythm, 2014-07
HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.
Circulation journal : official journal of the Japanese Circulation Society, 2019 Oct 09
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version.
Arrhythmia & electrophysiology review, 2020 Dec
Management of Cardiac Sarcoidosis in 2020.
Arthritis Rheumatol, 2021 Jul
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2021 Nov 12
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2013 Nov-Dec
CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation.
European respiratory review : an official journal of the European Respiratory Society, 2021 Nov 08
Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review.
Lancet Respir Med, 2023 Jan
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
JAMA neurology, 2018-12-01
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.
Journal of neuroimmunology, 2022 Apr 09
Peripheral neuropathy in sarcoidosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015-08-01
Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 24
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).
Expert review of respiratory medicine, 2023 Jun 23
Diagnostic accuracy of interleukin-2 receptor in sarcoidosis: a systematic review and meta-analysis.
Current opinion in pulmonary medicine, 2013 Sep
Common variable immunodeficiency-associated granulomatous and interstitial lung disease.
Annals of the rheumatic diseases, 2024 Jan 11
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08
Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
J Immunother Cancer, 2021 Jul
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07
Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
European journal of cancer (Oxford, England : 1990), 2023 Dec 28
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Arthritis and rheumatism, 2006 Mar
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Rheumatology (Oxford, England), 2021 Dec 24
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
Current opinion in pulmonary medicine, 2023 Jun 30
Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.
Rheumatology (Oxford, England), 2023 Feb 01
Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.
International journal of cardiology. Heart & vasculature, 2021 Apr 29
Non-steroidal treatment of cardiac sarcoidosis: A systematic review.
Lupus, 2014 Jul 30
Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections.
MMWR. Morbidity and mortality weekly report, 2024 Sep 12
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
Journal of the Endocrine Society, 2022 Dec 02
Perioperative Evaluation and Management of Patients on Glucocorticoids.
Diagnostics (Basel, Switzerland), 2021 Apr 20
Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.
JAMA otolaryngology-- head & neck surgery, 2020 Jan 01
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024 Mar 14
Medical Maintenance Therapy Following Laser Excision in Patients With Granulomatosis With Polyangiitis (GPA)-Associated Subglottic Stenosis.
The European respiratory journal, 2014 Aug 07
Sarcoidosis and subsequent cancer risk: a Danish nationwide cohort study.
Journal of clinical medicine, 2024 Jan 07
Infectious Complications of Pulmonary Sarcoidosis.
Rheumatology (Oxford),
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
Rheumatology (Oxford, England), 2023 Dec 01
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2004-03
Leflunomide for chronic sarcoidosis.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2000-03
Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.
Chest, 2003-07
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.
American journal of respiratory and critical care medicine, 2006-10-01
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
Diagnostics (Basel, Switzerland), 2024 Jan 23
A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis.
Chest, 1999 Aug
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group.
Respiration; international review of thoracic diseases, 2012 Dec 29
Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study.

Related Topics in Pulmonology

Copyright © 2024 theMednet
All Rights Reserved.